



COMP endorses the Pan-Canadian Collaboration for Quality Assurance in Radiopharmaceutical Therapy (PCQRT)

April 3, 2025

A Pan-Canadian Expert panel was assembled in 2023-24 to guide the development of Pan-Canadian Quality Assurance Guidelines in radiopharmaceutical therapy (RPT). This consensus-based guideline is designed to be a living document that acts as a benchmarking tool for centres providing radiopharmaceutical therapy across Canada. Centres can benefit from evaluating their own performance, sharing results, and re-assessing in the future, leading to the evaluation of change in quality over time, and variance of quality of radiopharmaceutical therapy in Canada.

The Canadian Organization of Medical Physicists (COMP) officially endorsed the PCQRT on March 19, 2025, and has communicated its support to the Canadian Association of Provincial Cancer Agencies (CAPCA).

Radiopharmaceutical therapies deliver radiation to a specific target, much like radiation therapy, but are typically administered systemically and require specialized expertise. Recent advancements in theranostic radiopharmaceuticals have improved treatment targeting and offered more options for patients with limited choices. COMP's endorsement of these guidelines reinforces medical physicists' essential role in coordinated patient care teams to ensure safe delivery and effective planning to minimize the impact of potential adverse events.

The guideline can be accessed [here](#).